Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zentalis Pharmaceuticals Inc (NQ: ZNTL )

4.110 +0.170 (+4.31%)
Streaming Delayed Price Updated: 11:08 AM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zentalis Pharmaceuticals Inc

< Previous 1 2 3 Next >
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets
(ZNTL) - Analyzing Zentalis Pharma's Short Interest
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Analyst Expectations for Zentalis Pharma's Future
Via Benzinga
Where Zentalis Pharma Stands With Analysts
Via Benzinga
Analyst Expectations for Zentalis Pharma's Future
Via Benzinga
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Zentalis Pharmaceuticals announced the FDA's partial clinical hold on azenosertib studies due to recent patient deaths. 
Via Benzinga
Exposures Product Safety
Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes
Via Benzinga
Where Zentalis Pharma Stands With Analysts
Via Benzinga
Zentalis Pharma: Q1 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024
ZNTL stock results show that Zentalis Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
From Immunome, Inc.
Via Business Wire
Morgan Stanley Maintains Overweight Rating for Zentalis Pharma: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Around $108M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
5 Short Squeeze Stocks In Play Thursday: Nikola, Verve, Carvana, More
Via Benzinga
Domino's Pizza, Patterson-UTI Energy, JinkoSolar And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 180 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) jumped 19.9% to... 
Via Benzinga
Why Shares of Zentalis Pharmaceuticals Dropped This Week
A rash of insider selling meant the stock gave back some of its gains from last week. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Friday
  On Friday, 497 companies set new 52-week lows. 
Via Benzinga
Newman Ferrara LLP Announces Corporate Governance Investigations of Zentalis Pharmaceuticals, Inc. (ZNTL)
From Newman Ferrara LLP
Via Business Wire
4 Analysts Have This to Say About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (NASDAQ:ZNTL) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Oppenheimer Maintains Outperform Rating for Zentalis Pharmaceuticals: Here's What You Need To Know
Oppenheimer has decided to maintain its Outperform rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) and lower its price target from $80.00 to $50.00. Shares of Zentalis Pharmaceuticals are trading up... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.